Specifically, we aim to investigate the potential effects of NBP14, compared to T30, in modulating the expression pattern of the endogenous T14, its receptor target and the familiar AD markers, Aβ, and p-Tau. This evidence concerns the gene MAPT and Alzheimer disease.